Ripretinib

Ripretinib is an inhibitor of receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA). In vitro kinase inhibition studies show that ripretinib inhibits wild-type KIT and PDGFRA with IC₅₀ values of 3 and 3.6 nM. It is approved for the treatment of adult patients with advanced gastrointestinal stromal tumour who have received prior treatment with 3 kinase inhibitors.